Synthaverse (LTS:0RKM) SpecialCharges

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RKM Synthaverse SA LTS:0RKM
55 GF Score
Price zł5.30
GF Value zł5.39
! 8 Warning Signs
View Full Analysis

What is Synthaverse SpecialCharges?

Special Charges only applies to banks.

LTS:0RKM
55GF Score
Synthaverse SA LTS:0RKM
SpecialCharges is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Synthaverse (LTS:0RKM) Overvalued in 2026?

Based on GuruFocus' analysis, Synthaverse stock appears to be undervalued. The current stock price of zł5.30 is trading 1.7% below its estimated GF Value™ of zł5.39.

Key valuation signals for LTS:0RKM:

  • SpecialCharges:
  • GF Value™: zł5.39 vs. price of zł5.30 (1.7% below fair value)
  • GF Score™: 55/100 with 8 warning signs

No single metric tells the full story. See the LTS:0RKM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Synthaverse Business Description

Other Exchanges SVE:Poland6NQ:Germany
Address 10, Uniwersytecka street, Lublin, POL, 20-029
Synthaverse SA is a Polish pharmaceutical and biotechnology company based in Lublin, formerly known as Bioton. It develops, manufactures, and sells prescription drugs and medical devices, with a focus on oncology, urology, and wound care. Its best-known product is Onko BCG, a BCG-based immunotherapy used in the treatment of non-muscle-invasive bladder cancer, which is sold in Poland and exported to numerous international markets. The company also produces wound-care and dermatological preparations and offers contract manufacturing services. Revenue comes from sales of its own branded pharmaceutical products, exports, and manufacturing services for third parties. Synthaverse sells primarily to hospitals, clinics, wholesalers, and pharmaceutical distributors, with its main market in Poland and growing sales across Europe, Asia, and other regions.
55GF Score

Get the complete analysis for LTS:0RKM

SpecialCharges is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł5.30
Price
zł5.39
GF Value